X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Patients support state action requiring PBMs and insurers to share savings and cap costs for medicines

By Stami Williams  |    June 16, 2022
Patient concerns over ever-increasing costs are growing, especially when it comes to their health care. Morning Consult recently conducted a 50-state poll of 20,000 Americans on behalf of PhRMA to...   Read More

New poll shows voters sounding the alarm on health insurance companies and PBMs

By Cynthia Hicks  |    June 6, 2022
Many Americans battle with an illness every day, but unfortunately for some, their illness is not the only battle they face. A recent Morning Consult/PhRMA poll of 2,004 registered voters shows that...   Read More

In comments to federal agency, PhRMA warns of the growing influence of middlemen over patient access and out-of-pocket costs for prescription medicines

By Brian Newell  |    May 31, 2022
In comments submitted to the Federal Trade Commission (FTC), PhRMA urged the agency to examine how pharmacy benefit managers (PBMs) leverage their extraordinary power to maximize profits, often in...   Read More

Government price setting won’t stop insurers from shifting costs to patients

By Nicole Longo  |    February 2, 2022
The drug pricing provisions in the Build Back Better Act (BBBA) would allow the government to set the price of certain medicines in Medicare. This is a misguided approach that threatens future...   Read More

New insulin report highlights how incentives benefit middlemen, harm patients

By Brian Newell  |    January 22, 2021
The Senate Finance Committee has released a new report detailing findings of their investigation into the role that market dynamics play in the pricing of insulins. The report conclusions further...   Read More

Key facts: The final rebate rule will be a positive change for patients

By Tom Wilbur  |    January 19, 2021
While drug middlemen are making billions of dollars in record profits at a time when millions of Americans are facing financial struggles, they are also suing to block the final rebate rule, a policy...   Read More

PhRMA submits comments on ways to refocus the 340B program on America’s vulnerable patients

By Nicole Longo  |    November 2, 2020
In response to the Request for Input on Modernizing the 340B Drug Pricing Program issued by Representative Greg Walden and Senator Lamar Alexander, PhRMA has outlined a number of commonsense ways...   Read More

Study finds middlemen excluded nearly 850 medicines from formularies this year

By Katie Koziara  |    September 17, 2020
A new study from Xcenda finds that from 2014 to 2020, the number of medicines excluded by at least one of the three largest pharmacy benefit managers (PBMs) from their standard formularies increased...   Read More

PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs

By Holly Campbell  |    March 3, 2020
Yesterday, PhRMA submitted comments on the Department of Health & Human Services’ (HHS) 2021 Notice of Benefit and Payment Parameters proposed rule. The proposed rule would hurt  patients’ ability to...   Read More

340B Spotlight: How for-profit middlemen are taking advantage of a program meant to support nonprofit entities and patients

By Nicole Longo  |    August 20, 2019
Congress created the 340B program to help safety-net providers, like federally-funded safety net clinics, access discounts on prescription medicines for vulnerable or uninsured patients....   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates